Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Avidity Biosciences Inc shares valued at $27,549 were sold by Gallagher Kathleen P. on Jun 17 ’25. At $30.24 per share, Gallagher Kathleen P. sold 911 shares. The insider’s holdings dropped to 50,392 shares worth approximately $1.72 million following the completion of this transaction.
Also, KATHLEEN GALLAGHER purchased 911 shares, netting a total of over 27,148 in proceeds.
Before that, Flanagan W. Michael had sold 20,000 shares from its account. In a trade valued at $657,694, the Chief Scientific Officer traded Avidity Biosciences Inc shares for $32.88 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $2.73 million.
Analysts at Bernstein started covering the stock with ‘”an Outperform”‘ outlook in a report released in late June. As of June 17, 2025, Wolfe Research has initiated its “an Outperform” rating for RNA. Earlier on June 11, 2025, Raymond James initiated its rating. Their recommendation was “a Strong buy” for RNA stock.
Analyzing RNA Stock Performance
On last trading session,, Avidity Biosciences Inc [NASDAQ: RNA] rose 1.52% to $34.04. The stock’s lowest price that day was $32.81, but it reached a high of $34.54 in the same session. During the last five days, there has been a surge of approximately 8.17%. Over the course of the year, Avidity Biosciences Inc shares have dropped approximately -25.38%.
Support And Resistance Levels for Avidity Biosciences Inc (RNA)
RSI (Relative Strength Index) is 63.10 on the 14-day chart, showing neutral technical sentiment.
Is Avidity Biosciences Inc subject to short interest?
Stocks of Avidity Biosciences Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.56 million shares to 16.34 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 15.79 million shares. A jump of 3.41% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.56 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.56.
Which companies own the most shares of Avidity Biosciences Inc (RNA)?
In terms of Avidity Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 70 in the next 12 months, up nearly 108.77% from the previous closing price of $33.53. Analysts anticipate Avidity Biosciences Inc stock to reach 70 by 2025, with the lowest price target being 70. In spite of this, 6 analysts ranked Avidity Biosciences Inc stock as Buy at the end of 2025. On March 13, 2025, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $70.
